GSK Ventures: Recycling R&D Assets

GSK's Ventures swaps unexploited and non-core R&D assets for equity in promising young companies, giving their programs a second chance in someone else's hands-at no cost.

Osagie Imasogie, VP and Director of GSK Ventures, explains that his group is just like any other venture capital firm focused on deploying assets to maximize returns to investors. But rather than investing cash in up-and-coming businesses and duplicating the efforts of the many and varied cash-based VCs in the market, including GlaxoSmithKline PLC 's corporate venture capital arm, SR One Ltd., Ventures instead invests non-core assets from GSK's R&D operations.

Imasogie believes that Ventures has found a niche. There's already plenty of cash in VCs' pockets to back promising companies,...

In Vivo Podcast

Candid conversations with C-suite leaders.

Keep up with strategy, innovation and evolving trends across life science industries.

More from Global Vision

More from In Vivo